Market Trends of Cellular Health Screening Industry
This section covers the major market trends shaping the Cellular Health Screening Market according to our research experts:
Telomere Tests Segment is Expected to Hold Significant Market Share Over the Forecast Period
The telomere test for a significant share of the cellular health screening market as these panels are used to get more accurate information and help perform cellular health screening tests to measure the length of the telomere, thereby preventing diseases. Furthermore, with the rising geriatric population, the preference for telomere tests is expected to rise as it facilitates individuals to check their cellular age and thereby take preventive measures, contributing to the growth of the market.
According to the Frontiers research study published in January 2021, telomere had been the most widely used molecular biomarker of aging. Innovative approaches, such as single-cell telomere measurement techniques aimed at the identification of critically short telomeres and DNA methylation-based methods of telomere length estimation, were being developed to improve the sensitivity, repeatability, and throughputs of methods. Such uses of telomere-based tests and developments of improved sensitivity telomere tests are expected to contribute to the growth of the segment over the forecast period.
The rise in the market player's activities, such as product launches, to meet the growing demand for telomere tests is expected to contribute to the segment's growth. For instance, in August 2021, TruDiagnostics released a new report expansion for TruAge, its epigenetic testing service. This expansion gives an accurate estimation of telomere length based on methylation. Thus, the above-mentioned factors are expected to contribute to the growth of the segment over the forecast period.
Therefore, factors such as innovations in telomere tests and rising initiatives by key players for the launch of telomere tests are expected to drive segment growth.
North America is Expected to Dominate the Cellular Health Screening Market Over the Forecast Period
North America is expected to hold a significant share of the cellular health screening market owing to a high patient pool and rising disease prevalence.
According to the American Cancer Society, in 2022 estimated that a total of 1.9 million new cancer cases would occur in the United States in 2022. Such increasing incidence of chronic diseases among the population is expected to drive the demand for cellular health screening owing to the effective and early diagnosis, thereby contributing to the growth of the market.
In addition, the Centres for Disease Control and Prevention (CDC) data updated in July 2022 showed that coronary heart disease was the most common type of heart disease, and approximately 20.1 million adults of age 20 and older had the disease in the United States. As per the CDC data in October 2022, every 40 seconds, someone suffers from a heart attack, and nearly 805,000 people in the United States have a heart attack every year. Thus, the high burden of cardiovascular diseases demands the availability of cellular health screening for early diagnosis, driving the market's growth.
Furthermore, in June 2021, Grail launched a single blood test capable of detecting the presence of multiple cancers with the Galleri diagnostic. The test is meant to screen people who may already have an elevated risk for cancer, such as adults over the age of 50. such initiatives from the key market players lead to increased adoption of cellular health screening in the region, driving market growth.
